These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11464254)

  • 21. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.
    Tsuchihashi T; Ueno M; Tominaga M; Kajioka T; Onaka U; Eto K; Goto K
    Clin Exp Hypertens; 2005 Nov; 27(8):583-91. PubMed ID: 16303635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium channel blockers in treatment of hypertension.
    Muntwyler J; Follath F
    Prog Cardiovasc Dis; 2001; 44(3):207-16. PubMed ID: 11727278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High blood pressure and calcium antagonism.
    Palma-Gámiz JL
    Cardiology; 1997; 88 Suppl 1():39-46. PubMed ID: 9118167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelium, atherosclerosis and calcium channel blockers.
    Biswas TK
    J Indian Med Assoc; 2003 Jul; 101(7):428-31. PubMed ID: 14748381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium channel blockers and nephroprotection.
    Ungar A; Di Serio C; Lambertucci L; Monami M; Masotti G
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):31-9. PubMed ID: 16640171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M; Takagi T; Ito N; Terai M; Tatara Y; Hayashi N; Shiota A; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
    J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y; Jacob RF; Mason RP
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium channel blockers and coronary heart disease.
    Inzitari M; Di Bari M; Marchionni N
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):6-15. PubMed ID: 16640169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists.
    Nap A; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2004 Jun; 18(3):309-19. PubMed ID: 15147282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects.
    Angeli F; Verdecchia P; Reboldi GP; Gattobigio R; Bentivoglio M; Staessen JA; Porcellati C
    Am J Hypertens; 2004 Sep; 17(9):817-22. PubMed ID: 15363825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Calcium channel blockers in the treatment of cardiovascular disease].
    Halawa B
    Pol Merkur Lekarski; 2001 Jul; 11(61):83-7. PubMed ID: 11579840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.
    Takahara A
    Cardiovasc Ther; 2009; 27(2):124-39. PubMed ID: 19426250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients.
    Farah R; Shurtz-Swirski R
    Minerva Cardioangiol; 2008 Oct; 56(5):467-76. PubMed ID: 18813182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.